Henry Ford Health System

West Bloomfield, Michigan 48322

1 studies enrolling now · 13 studies all time

What they study most

Abdominal Pain, Brain Diseases, Central Nervous System Diseases, Chronic Hepatitis C Virus Infection, Clostridium Infections, Colonoscopy, Covid19, Crohn Disease, Essential Tremor, Headache Disorders, Headache Disorders, Primary, Migraine Disorders

Studies at this site

• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) — Recruiting now
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease — Running, not enrolling
• Pregabalin for Abdominal Pain From Adhesions — Stopped early
• Prospective Study for Symptomatic Relief of ET With Cala Therapy — Completed
• Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection — Stopped early
• The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study — Stopped early
• Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease — Completed
• Study of Urate Elevation in Parkinson's Disease, Phase 3 — Completed
• Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone — Stopped early
• Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy — NO_LONGER_AVAILABLE
• Study of CTS-1027 in Hepatitis C Patients — Completed